Therapeutic drug repurposing, repositioning and rescue - Part I: Overview

Drug Discovery World

Volumn 16, Issue 1, 2014, Pages 49-62

  Naylor, Stephen ^a   Schonfeld, Judge M ^b  

^a MaiHealth Inc   (United States)

^b CureHunter Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; GENERIC DRUG; INSULIN SENSITIZING AGENT; MLR 1023; NEW DRUG; ROFECOXIB; UNCLASSIFIED DRUG; VACCINE;

CONSENSUS; CONSUMER; COST; DRUG INDUSTRY; DRUG REPOSITIONING; HEALTH CARE SYSTEM; HUMAN; NOMENCLATURE; NONHUMAN; REVIEW;

EID: 84924242663     PISSN: 14694344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. PriceWaterhouseCoopersPharma 2020. i) The Vision; ii) Virtual R&D; iii) Marketing the Future; iv) Challenging Business Models; v) Taxing Times Ahead; vi) Supplying the Future vii) Introducing the Pharma 2020 Series. http://www.pwc.com/gx/en/pharma-life-sciences/pharma2020/index.jhtml.
2. Cost to Develop and Win Marketing Approval for a New Drug Is $2.6 Billion. Tufts CSDD. http://csdd.tufts.edu/news/complete-story/pr-tufts-csdd-2014-cost-study.
3. Paul, SM et al. How to Improve R&D Productivity: the Pharmaceutical Industry's Grand Challenge. Nature Reviews: Drug Discovery, 9, 203-214 (2010).
4. Deloitte Centre for Health solutions. Measuring the Return from Pharmaceutical Innovation 2014. Turning a Corner? http://www2.deloitte.com/content/dam/Deloitte/uk/Documents/life-sciences-health-care/measuring-the-return-from-pharmaceutical-innovation-2014.pdf.
5. Gavura, S. What Does a New Drug Cost? Part II The Productivity Problem. http://www.sciencebasedmedicine.org/what-does-a-new-drug-cost-part-ii-the-productivity-problem.
6. Hay, M et al. Clinical Development Success Rates for Investigational Drugs. Nature Biotech. 32, 40-51 (2014).
7. Cook, D et al. Lessons Learned from the Fate of Astra-Zeneca's Drug Pipeline: A Five Dimensional Network. Nature Reviews: Drug Discovery. 13, 419-431 (2014).
8. Naylor, S. NostraPharmus Revisitied: A Future of Splendid Isolation or Multilevel Participation for Pharmaceutical Companies. Drug Discov. World. Summer Supplement, 24-26 (2010).
9. Accenture Life Sciences. Beyond the Patent Cliff-Signs of Recovery in BioPharma's New Normal. http://www.accenture.com/SiteCollectionDocuments/PDF/Accenture-Life-Sciences-Beyond-The-Patent-Cliff-Signs-Of-Recovery-in-Biopharmas-New-Normal.pdf.
10. Kessel, M. Restoring the Pharmaceutical Industry's Reputation. Nature Biotech. 32, 983-990 (2014).
11. Murteira, S, Ghezaiel, Z, Karray, S and Lamure, M. Drug Reformulations and Repositioning in Pharmaceutical Industry and its Impact on Market Access: Reassessment of Nomenclature. Journal of Market Access & Health Policy 1:21131 - http://dx.doi.org/10.3402/jmahp.v1i0.21131 (2013).
12. Barratt, MJ and Frail, DE (Eds). Drug Repositioning: Bringing New Life to Shelved Assets and Existing Drugs. John Wiley & Sons, Hoboken, NJ, USA. (2012).
13. Jin, G and Wong, STC. Toward Better Drug Repositioning: Prioritizing and Integrating Existing Methods into Efficient Pipelines. Drug Dis. Today 19, 637-644 (2014).
14. Persidis, A. Personal Communication. Data to be published in Drug Repurposing Rescue & Repositioning. (2015).
15. Persidis, A and Mucke, HAM (Eds). Drug Repurposing, Rescue & Repositioning. http://www.liebertpub.com/overview/drug-repurposing-rescue-brand-repositioning/627.
16. Lederman, S. Drug Repurposing Rekindles Promise. GEN. January 30th 2013. http://www.genengnews.com/gen-articles/drug-repurposing-rekindles-promise/4710/?kwrd=Drug%20Repositioning.
17. Beachy, SH, Johnson, SG, Olson, S and Berger, AC (Eds). Drug Repurposing and Drug Repositioning-Workshop Summary. National Academies Press, Washington DC, USA (2014).
18. Naylor, S. Overview of Biomarkers in Disease, Drug Discovery and Development. Drug Discov. World. Spring Edition: 21-30 (2005).
19. Naylor, S and Cole, T. Overview of Companion Diagnostics in the Pharmaceutical Industry. Drug Discov. World. Spring Edition: 67-79 (2010).
20. Naylor, S and Cole, T. Companion Diagnostics in the Pharmaceutical Industry: Part II Business Models Drug Discov. World Summer Edition: 61-68 (2010).
21. Mucke, HAM. A New Journal for the Drug Repurposing Community. Drug Repurposing, Rescue & Repositioning 1, 3-4 (2014).
22. Sekhon, BS. Repositioning Drugs and Biologics; Retargeting Old/Existing for Potential New Therapeutic Applications. J. Pharm. Educ. Res. 4, 1-15 (2013).
23. Sukkar, E. Still Feeling the Vioxx Pain. Pharm. J. September 14th, 2014. http://www.pharmaceuticaljournal.com/news-and-analysis/feature/still-feeling-the-vioxx-pain/20066485.article.
24. Thayer, AN. Drug Repurposing. Chem. & Eng. News 90, 15-25 (2012).
25. Fierce Biotech. Roche and Broad Band Together to Bring Failed Drugs Back from the Dead. http://www.fiercebiotech.com/story/roche-broad-band-together-bring-failed-drugs-back-dead/2012-11-28.
26. Huang, R et al.The NCGC Pharmaceutical Collection: A Comprehensive Resource of Clinically Approved Drugs Enabling Repurposing and Chemical Genomics. Science Translational Medicine 3, 80ps16.doi:10.1126/scitranslmed.3001862 (2011).
27. Bloom, B. Cures Within Reach. Personal Communication.
28. Allarakhia, M. Open source Approaches for the Repurposing of Existing or Failed Candidate Drugs: Learning From and Applying the Lessons Across Diseases. Drug Design Develop. Ther. 7, 753-766 (2013).
29. Loging, W. Cheminformatic/Bioinformatic Analysis of Large Corporate Databases: Application to Drug Repurposing. Drug Dis. Today 8, 109-116 (2011).
30. Haupt, VJ, Daminelli, S and Schroeder, M. Drug Promiscuity in PDB: Protein Binding Site Similarity Is Key. PLoS ONE 8, (2013). http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0065894.
31. Hu, Y and Bajorath, J. Monitoring Drug Promiscuity Over Time. F1000Research 3, (2014), Last updated: 05 JAN 2015. http://f1000research.com/articles/3-218/v2.
32. Li, YY and Jones, SJM. Drug Repositioning for Personalized Medicine. Genome Medicine 4, 27-41 (2012).
33. Murteira, S, Millier, A, Ghezaiel, Z and Lamure, M. Drug Reformulations and Repositioning in the Pharmaceutical Industry and Their Impact on Market Access: Regulatory Implications. Journal of Market Access & Health Policy 2, (2014) http://dx.doi.org/10.3402/jmahp.v2.22814.
34. Padhy, BM and Gupta, YK. Drug Repositioning: Re-Investigating Existing Drugs for New Therapeutic Indications. J. Postgrad. Med. 57, 153-60 (2011).
35. Wang, S-Y, Calderon, J and Wang GK. Block of Neuronal Na+ Channels by the Antidepressant Duloxetine in a State-Dependent Manner. Pain Medicine 113, 655-665 (2010).
36. Persidis, A. The Benefits of Drug Repositioning. Drug Discov. World Spring Edition: 9-12 (2011).
37. Knowledge-Based Drug Repositioning to Drive R&D Productivity. Thompson Reuters (2012). http://thomsonreuters.com/products/ip-science/04-038/drug-repositioning-cwp-en.pdf.
38. Naylor, S, Kauppi, DM and Schonfeld, JM. Therapeutic Drug Repurposing, Repositioning, and Rescue: Part II- Regulatory, Intellectual Property and Business Considerations. Drug Discov. World In Press (2015).
39. Sirk, K. Everything Old is New Again. Drug Discov. News 10, (2014). http://www.ddn-news.com/index.php/newsarticle=6045.